EDWARDS LIFESCIENCES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.05 USD | +0.95% |
|
-3.22% | +18.10% |
| Apr. 16 | Market sentiment sours |  |
| Apr. 16 | ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca | |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
89.2
USD
Average target price
94.52
USD
Spread / Average Target
+5.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.10% | 53.69B | |
| +4.48% | 213B | |
| +3.89% | 177B | |
| +12.21% | 134B | |
| +17.83% | 99.13B | |
| +0.11% | 63.47B | |
| -4.51% | 46.36B | |
| -1.60% | 41.09B | |
| +11.07% | 39.3B | |
| +7.46% | 27.19B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Edwards Lifesciences : Piper Sandler Adjusts Price Target on Edwards Lifesciences to $120 From $105, Keeps Overweight Rating
